Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis

Detalhes bibliográficos
Autor(a) principal: Ferreto,Lirane Elize Defante
Data de Publicação: 2021
Outros Autores: Bortoloti,Durcelina Schiavoni, Fortes,Paulo Cezar Nunes, Follador,Franciele, Arruda,Gisele, Ximenez,João Paulo, Wendt,Guilherme Welter
Tipo de documento: Relatório
Idioma: eng
Título da fonte: São Paulo medical journal (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802021000600657
Resumo: ABSTRACT BACKGROUND: Considering the disruptions imposed by lockdowns and social distancing recommendations, coupled with overwhelmed healthcare systems, researchers worldwide have been exploring drug repositioning strategies for treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). OBJECTIVE: To compile results from randomized clinical trials on the effect of dexamethasone, compared with standard treatment for management of SARS-CoV-2. DESIGN AND SETTING: We conducted a systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines in a Brazilian public university. METHODS: We sought to compile data from 6724 hospitalized patients with confirmed or suspected SARS-CoV-2 infection. RESULTS: Treatment with dexamethasone significantly reduced mortality within 28 days (risk ratio, RR: 0.89; 95% confidence interval, CI: 0.82-0.97). Dexamethasone use was linked with being discharged alive within 28 days (odds ratio, OR: 1.20; 95% CI: 1.07-1.33). CONCLUSIONS: This study suggests that dexamethasone may significantly improve the outcome among hospitalized patients with SARS-CoV-2 infection and associated severe respiratory complications. ­Further studies need to consider both dose-dependent administration and outcomes in early and later stages of the disease. PROSPERO platform: CRD42021229825.
id APM-1_3282d7cc776357e2e1db04b89afce032
oai_identifier_str oai:scielo:S1516-31802021000600657
network_acronym_str APM-1
network_name_str São Paulo medical journal (Online)
repository_id_str
spelling Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysisDexamethasoneCOVID-19SARS-CoV-2Meta-analysis [publication type]Pulmonary medicineCoronavirus pandemicDrug repurposingRespiratory medicineClinical trialsABSTRACT BACKGROUND: Considering the disruptions imposed by lockdowns and social distancing recommendations, coupled with overwhelmed healthcare systems, researchers worldwide have been exploring drug repositioning strategies for treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). OBJECTIVE: To compile results from randomized clinical trials on the effect of dexamethasone, compared with standard treatment for management of SARS-CoV-2. DESIGN AND SETTING: We conducted a systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines in a Brazilian public university. METHODS: We sought to compile data from 6724 hospitalized patients with confirmed or suspected SARS-CoV-2 infection. RESULTS: Treatment with dexamethasone significantly reduced mortality within 28 days (risk ratio, RR: 0.89; 95% confidence interval, CI: 0.82-0.97). Dexamethasone use was linked with being discharged alive within 28 days (odds ratio, OR: 1.20; 95% CI: 1.07-1.33). CONCLUSIONS: This study suggests that dexamethasone may significantly improve the outcome among hospitalized patients with SARS-CoV-2 infection and associated severe respiratory complications. ­Further studies need to consider both dose-dependent administration and outcomes in early and later stages of the disease. PROSPERO platform: CRD42021229825.Associação Paulista de Medicina - APM2021-12-01info:eu-repo/semantics/reportinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802021000600657Sao Paulo Medical Journal v.139 n.6 2021reponame:São Paulo medical journal (Online)instname:Associação Paulista de Medicinainstacron:APM10.1590/1516-3180.2021.0120.r1.30062021info:eu-repo/semantics/openAccessFerreto,Lirane Elize DefanteBortoloti,Durcelina SchiavoniFortes,Paulo Cezar NunesFollador,FrancieleArruda,GiseleXimenez,João PauloWendt,Guilherme Weltereng2021-11-10T00:00:00Zoai:scielo:S1516-31802021000600657Revistahttp://www.scielo.br/spmjhttps://old.scielo.br/oai/scielo-oai.phprevistas@apm.org.br1806-94601516-3180opendoar:2021-11-10T00:00São Paulo medical journal (Online) - Associação Paulista de Medicinafalse
dc.title.none.fl_str_mv Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis
title Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis
spellingShingle Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis
Ferreto,Lirane Elize Defante
Dexamethasone
COVID-19
SARS-CoV-2
Meta-analysis [publication type]
Pulmonary medicine
Coronavirus pandemic
Drug repurposing
Respiratory medicine
Clinical trials
title_short Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis
title_full Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis
title_fullStr Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis
title_full_unstemmed Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis
title_sort Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis
author Ferreto,Lirane Elize Defante
author_facet Ferreto,Lirane Elize Defante
Bortoloti,Durcelina Schiavoni
Fortes,Paulo Cezar Nunes
Follador,Franciele
Arruda,Gisele
Ximenez,João Paulo
Wendt,Guilherme Welter
author_role author
author2 Bortoloti,Durcelina Schiavoni
Fortes,Paulo Cezar Nunes
Follador,Franciele
Arruda,Gisele
Ximenez,João Paulo
Wendt,Guilherme Welter
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Ferreto,Lirane Elize Defante
Bortoloti,Durcelina Schiavoni
Fortes,Paulo Cezar Nunes
Follador,Franciele
Arruda,Gisele
Ximenez,João Paulo
Wendt,Guilherme Welter
dc.subject.por.fl_str_mv Dexamethasone
COVID-19
SARS-CoV-2
Meta-analysis [publication type]
Pulmonary medicine
Coronavirus pandemic
Drug repurposing
Respiratory medicine
Clinical trials
topic Dexamethasone
COVID-19
SARS-CoV-2
Meta-analysis [publication type]
Pulmonary medicine
Coronavirus pandemic
Drug repurposing
Respiratory medicine
Clinical trials
description ABSTRACT BACKGROUND: Considering the disruptions imposed by lockdowns and social distancing recommendations, coupled with overwhelmed healthcare systems, researchers worldwide have been exploring drug repositioning strategies for treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). OBJECTIVE: To compile results from randomized clinical trials on the effect of dexamethasone, compared with standard treatment for management of SARS-CoV-2. DESIGN AND SETTING: We conducted a systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines in a Brazilian public university. METHODS: We sought to compile data from 6724 hospitalized patients with confirmed or suspected SARS-CoV-2 infection. RESULTS: Treatment with dexamethasone significantly reduced mortality within 28 days (risk ratio, RR: 0.89; 95% confidence interval, CI: 0.82-0.97). Dexamethasone use was linked with being discharged alive within 28 days (odds ratio, OR: 1.20; 95% CI: 1.07-1.33). CONCLUSIONS: This study suggests that dexamethasone may significantly improve the outcome among hospitalized patients with SARS-CoV-2 infection and associated severe respiratory complications. ­Further studies need to consider both dose-dependent administration and outcomes in early and later stages of the disease. PROSPERO platform: CRD42021229825.
publishDate 2021
dc.date.none.fl_str_mv 2021-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/report
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format report
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802021000600657
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802021000600657
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/1516-3180.2021.0120.r1.30062021
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Paulista de Medicina - APM
publisher.none.fl_str_mv Associação Paulista de Medicina - APM
dc.source.none.fl_str_mv Sao Paulo Medical Journal v.139 n.6 2021
reponame:São Paulo medical journal (Online)
instname:Associação Paulista de Medicina
instacron:APM
instname_str Associação Paulista de Medicina
instacron_str APM
institution APM
reponame_str São Paulo medical journal (Online)
collection São Paulo medical journal (Online)
repository.name.fl_str_mv São Paulo medical journal (Online) - Associação Paulista de Medicina
repository.mail.fl_str_mv revistas@apm.org.br
_version_ 1754209268085555200